Ueland, Thor http://orcid.org/0000-0001-5005-0784
Gullestad, Lars
Kou, Lei
Young, James B.
Pfeffer, Marc A.
van Veldhuisen, Dirk Jan
Swedberg, Karl
Mcmurray, John J. V.
Desai, Akshay S.
Anand, Inderjit S.
Aukrust, Pål
Funding for this research was provided by:
University of Oslo
Article History
Received: 18 August 2020
Accepted: 15 September 2021
First Online: 5 October 2021
Declarations
:
: I.S.A., D.J.v.V., J.B.Y., J.J.V.M.: members of the RED‐HF Executive Committee (no payments in the last 12 months). M.P.: member of the RED‐HF Clinical Endpoint Committee and Executive Committee (no payments in the last 12 months); grants from Novartis and Sanofi; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, DalCor, Gilead, GalaxoSmithKline, Janssen, Lilly USA, The Medicines Company, Merck, Novartis, Novo Nordisk, Relypsa, Sanofi, Thrasos, Genzyme and Teva; The Brigham and Women's Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis. K.S.: consulting fees from AstraZeneca, Amgen, Novartis, Servier, Vifor Pharma; member of the RED‐HF Executive Committee (no payments in the past 12 months). A.S.D.: grant to the institution to support endpoint adjudication activities from Amgen; grant from Novartis; consulting fees from Novartis, St Jude/Abbott, Relypsa, Janssen, AstraZeneca, Sanofi, Cheetah Medical. J.J.V.M.: consulting fees from Cytokinetics/Amgen; grant from Amgen. All other authors have no conflict of interest.
: The trial complied with the Declaration of Helsinki and was approved by the Ethics Committees of the participating hospitals.
: All patients provided written informed consent.
: The provided information is anonymous and does not expose the identity of the patient.